Virtual Investor Event
Join Hansa Biopharma for an investor event featuring two KOLs discussing unmet need and current treatment landscape for Guillain-Barré syndrome (GBS).
June 16, 14:00 CEST/8:00 AM ET
Register and attendMedia
Regulatory press release
26/05/2025
Regulatory press release
26/05/2025
14/05/2025
13/05/2025
Join Hansa Biopharma for an investor event featuring KOLs David R. Cornblath, MD (Johns Hopkins University), and Simon Rinaldi, MRCP(Neuro), PhD (University of Oxford), who will discuss the unmet need and current treatment landscape for Guillain-Barré syndrome (GBS), an acute, rare, paralyzing inflammatory disease of the peripheral nervous system.
Monday, June 16, 2025 | 14:00 CEST / 8:00 AM ET
Live Webcast
Our focus area
We aim to address unmet need in conditions where the IgG-driven immune response becomes harmful, or it interferes with the delivery of lifesaving and life altering therapies.
Autoimmune Deep Dive - Guillain-Barré Syndrome
Annual General Meeting 2025
Half-year Report for January-June 2025
Media articles
Our partnership model is focused in three key areas – drug discovery and development, commercialization and distribution / licensing.
PartnershipsReady for a new career? Check out our job opportunities.
For five years Hansa has been awarded the Great Place To Work designation by the independent institute Great Place To Work®, a global authority on workplace culture, employee experience and leadership behavior.
Job opportunities
